SARS-COV-2 INFECTION IN PRIMARY CARE: A SINGLE-CENTERED,

RETROSPECTIVE, OBSERVATIONAL STUDY

Δι	JT	Н)F	RS:

Pilar Galicia García de Yébenes¹; Juan José Gutiérrez Cuevas¹; Fang Fang Chen Chen¹; Laura Santos Larrégola¹; Alberto Manzanares Briega¹; Manuel Linares Rufo²

¹M. D. Medicina Familiar y Comunitaria. C. Salud Buenos Aires, Madrid, España

² M. D. Servicio de Microbiología, Hospital Universitario Principe de Asturias

Conflicts of Interest: The authors declare no potential conflicts of interest.

Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Contributorship: Not applied

Correspondence author: Pilar Galicia

Adress: Hospital Universitario Príncipe de Asturias. Servicio de Microbiología Clínica. Carretera

de Alcalá, s/n, 28805 Meco (Madrid);

Number: + 34 91 87 81 00

email: pilarteresa.galicia@salud.madrid.org

• Word count 2423 words

• Number of tables: 4

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

Purpose: to describe the clinical characteristics of patients with confirmed SARS-CoV-2 infection

in primary care and to analyze the predictive role of different risk factors on prognosis, especially

living conditions.

Methods: Retrospective longitudinal observational retrospective study by reviewing medical

records from a primary care center since March 1 to April 30, 2020. Case definition of confirmed

SARS-CoV-2 infection, sociodemographic data, clinical characteristics, comorbidity and living

conditions were collected. The statistical analysis consisted in description of the sample,

comparison of prognosis groups and analysis of prognostic factors.

Results. A sample of 70 patients with confirmed SARS-CoV-2 infection was obtained, with

comorbidity mainly related to arterial hypertension, overweight/obesity, hypercholesterolemia,

diabetes and chronic pulmonary pathology. Pneumonia was present in 66%. Exitus occurred in

14% of the sample. Factors associated with mortality were advanced age (84 vs 55; p<0.0001),

arterial hypertension (78% vs 41%; p=0.040), asthma-COPD (56% vs 13%; p=0.008) and atrial

fibrillation (56% vs 5%; p=0.001).

Conclusions. The study reflects the clinical practice of a primary care center. This kind of studies

are essential to strengthen and reorganize the Health System and to try to anticipate the

2

medium- to long-term consequences of COVID-19 on global health.

Keywords: COVID-19, Primary Care, Social Conditions

Abbreviations

- SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
- **COVID-19:** severe acute respiratory syndrome coronavirus 2
- PC: Primary care
- PCC: Primary care center
- **COPD**: chronic obstructive pulmonary disease
- NSAIDs: Nonsteroidal anti-inflammatory drugs
- **ACE inhibitors:** Angiotensin-converting enzyme inhibitors
- PCR: polymerase chain reaction

INTRODUCTION

The first cases of atypical pneumonia produced by a new betacoronavirus, SARS-CoV-2 (severe

acute respiratory syndrome coronavirus 2), a respiratory virus transmitted by droplets through

close contact with an infected person, aerosols, or through fomites in their immediate

environment, were described in December 2019 (1-3). A significant proportion of those infected

are asymptomatic but can also cause transmission, which constitutes an important challenge for

the control of the disease. (4).

The disease, known as COVID-19, has become a pandemic that, as of January 14, 2021, has

resulted in more than 90 million people infected and nearly 2 million deaths worldwide (5). The

clinical picture is highly variable, with mild involvement in up to 81% of cases, requiring hospital

admission in about 14%, and admission to the ICU in the remaining 5% (6). The most common

symptoms at the onset of the disease are cough, fever, dyspnea, malaise, anosmia and

dysgeusia. In addition, gastrointestinal symptoms, neurological manifestations,

hypercoagulability syndrome with venous thrombosis, and skin involvement may occur (4).

The incubation period is 3-6 days. In general, disease progression and the need for

hospitalization occur 7-8 days after the onset of symptoms, with rapid deterioration and severe

hypoxia indicating the presence of acute respiratory distress syndrome (ARDS). The severity of

the disease, characterized by a syndrome of hyperinflammation with cytokine release and

potential organ involvement, is mainly related to age and previous comorbidity, especially

hypertension, diabetes and cardiovascular disease (7, 8). On the other hand, some biological

markers of poor prognosis have been reported, such as lymphopenia and increased of D-dimer,

among others (4, 6). Imaging techniques can show from normal radiographs to peripherally

distributed bilateral alveolus-interstitial pneumonias (1, 9). Histology shows a significant

inflammatory infiltrate characterized by diffuse alveolar damage, capillary congestion, hyaline

membrane formation, and diffuse thrombosis of small pulmonary arteries (10). An overall case

fatality rate of about 2% has been published (6), although the figures vary greatly depending on

the population group considered

As it is an emerging virus, there is no specific treatment available, although different therapeutic

options have been used with varying results (11). Consequently, management consists mainly

of supportive measures and treatment of symptoms, with anti-inflammatory drugs, such as

dexamethasone, and some immunomodulators (12, 13). On the other hand, the prevention of

the disease is based on the control of the sources of infection with individual protection

measures (personal hygiene and masks) and the study of contacts, as well as on the use of public

health measures based on isolation, social distance and community contention (6, 14). In

addition, several vaccine prototypes have been developed (15) and are currently being

implemented with a population based strategy.

The main publications on COVID-19 have focused on the hospital management of the most

severe patients, with little information on the situation of patients in primary care (PC) and the

impact of the disease at this level of care. Bearing in mind that PC is the gateway to the system

and that 80% of those infected show a mild and self-limited clinical picture, it is essential to know

the burden of disease in order to better organize care circuits, and to evaluate possible

predictors that can help PC physicians to estimate the risk of hospitalization and possible

complications in patients with confirmed SARS-CoV-2 infection.

The purpose of this study is to describe the clinical characteristics of patients with confirmed

SARS-CoV-2 infection in primary care and to analyze the predictive role of different risk factors

5

on prognosis, especially living conditions.

METHODS

Study design and participants

This is a population-based retrospective and observational study based on data collection from

medical records of the population attended by a primary care centre (PCC) in Madrid (Spain).

The "Buenos Aires" PCC attends a population of 20,878 inhabitants of the Vallecas area,

organized into 12 adult patient quotas of approximately 1,700 patients each one. This is an

eminently urban population, with a medium-low socioeconomic level.

The target population consisted of all subjects attended by the center at the beginning of the

study. The accessible population consists of all persons with an active clinical history. For the

selection of subjects the following inclusion criteria were used: a) over 18 years of age; b)

belonging to the reference population of the PCC quotas; c) have been assisted at this PCC,

either in person or by telephone, between March 1 and April 30, 2020; and d) have a diagnosis

of SARS-CoV-2 infection confirmed by PCR (polymerase chain reaction) during the study period.

Data collection

We reviewed clinical electronic medical records for all patients with laboratory confirmed SARS-

CoV-2 infection. We collected data on sociodemographics (age, gender, country of origin);

comorbidity (high blood pressure, hypercholesterolemia, overweight, diabetes, cardiovascular

and ictus, renal failure, atrial fibrillation, hypothyroidism, dementia, malignancy, chronic

obstructive pulmonary disease (COPD) and smoking); concomitant treatments (ACE inhibitors,

steroids, NSAIDs); symptoms of SARS-CoV-2 infection (cough, dyspnea, fever, odynophagia,

headache, diarrhea, anosmia, ageusia, skin symptoms); radiological and laboratory findings on

admission (leukocyte, lymphocyte and platelet counts, ferritin, creatinkinase, procalcitonin, C-

reactive protein, transaminases, D-dimer, pro-BNP), treatment received; living conditions

(number of cohabitants, number of bathrooms in the house, elevator, type of transport, and job

6

position, number of times the household was left for shopping or leisure on a daily basis).

Variables. The outcome variable is poor prognosis, defined by exitus.

Statistical analysis

The purpose of the study is to describe the clinical characteristics and outcomes of patients.

Therefore, there were no formal hypotheses being implemented to drive the sample size

calculation and we included the maximum number of patients who met the inclusion criteria.

The description of the sample was expressed as measures of central tendency and dispersion,

as well as frequency and percentages for quantitative and qualitative variables, respectively.

Differences between exitus and non-exitus were assessed using two-sample t test o Wilcoxon

rank-sum test depending on parametric or non-parametric data for continuous variables and

Fisher's exact test for categorical variables. Tests were two-sided with significance set at alpha

less than 0.05.

The study was carried out in accordance with the Declaration of Helsinki and the international

standards, contained in the International Guidelines for Ethical Review of Epidemiological

Studies (Council for the International Organizations of Medical Sciences-CIOMS-Geneva, 1991)

and the recommendations of the Spanish Society of Epidemiology (SEE). The study was approved

by the local Clinical Research Ethics Committee (Comisión Local de Investigación Sureste). As

this is a retrospective study that does not involve a visit with the patient and the person who

has access to the clinical history is the physician in charge, the CEICm was asked to waive

informed consent for the patients.

RESULTS

The sample consisted of 70 patients with SARS-CoV-2 infection, confirmed by Ig G or PCR+, with

a mean age of 60 ± 21 years, 51.4% of whom were men. Most of them were Spanish (80%)

followed by those from Latin American countries (18%). In terms of occupation, most of them

were either unemployed or retired (53%), or belong to the socio-health sector (19%). The most

frequent comorbidities diagnosed in the clinical record were arterial hypertension (HT) (49%), overweight-obesity (47%), hypercholesterolemia (36%), diabetes mellitus (23%) and chronic pulmonary disease (asthma-CPD) (21%). Twenty-four percent of the patients were taking ACE inhibitors. The most common symptoms were cough (79%), fever (72%), dyspnoea (65%), headache (24%) diarrhea (24%), and less frequently ageusia (9%) and anosmia (8%) (table 1). Sixty-seven percent of the patients were referred to the hospital while 33% remained under primary care. As for the treatments received, the most common were hydroxychloroquine (74%), azithromycin or ceftriaxone-cefaxone (56%), and low molecular weight heparin (58%). Only 36% received specific antivirals such as lopinavir-ritonavir, with no use of remdesivir. Eleven percent were treated with corticosteroids. As for the analytical parameters, the number of patients for whom this information is available is very variable, although the median values of some of them are presented, such as leukocytes (6485), CRP (41), D-dimer (740), ferritin (510). Of the patients studied, 14% resulted in exitus. In the patients with chest x-ray, 66% had lobar/bilobar pneumonia (16%) or bilateral pneumonia (50%) (Table 2). Information on living conditions was not available for all patients. It is noteworthy that two patients lived with up to 20 people in the same household. Most household were equipped with just one bathroom (58%) and only 73% had an elevator. Eighty percent of the patients left home at least once a week and 76% went out daily. Twenty-seven percent used public transport. Among 65 patients with vital status information, 9 resulted in exitus (14%). Patients who died were older (mean age 84 vs 55; p<0.0001) and with higher prevalence of different risk factors as high blood pressure (78% vs 41%; p=0.040), asthma-COPD (56% vs 13%; p=0.008) and atrial fibrillation (56% vs 5%; p=0.001). In addition, the prevalence of overweight (71% vs 41%), stroke (22% vs 9%) and diabetes mellitus (33% vs 20%) was also higher among the exitus, although these differences did not reach statistical significance. On the other hand, no significant

differences were observed between exitus and non-exitus in the symptoms of presentation of

Covid infection, in the treatments received, or in their living conditions. However, there were

differences in derivation, since 100% of exitus occurred in the hospital, probably because they

were more severe patients (table 4).

The small sample size and the limited availability of information on some variables did not allow

us to study the determinants of mortality by multivariate regression analysis in order to estimate

the independent effect of possible predictors.

DISCUSSION

This retrospective population-based study describes the clinical characteristics of SARS-CoV-2

infection in a primary care center in the Madrid region and analyzes possible factors associated

with poor prognosis defined as exitus.

The results of this study show an overall mortality of 13.8%, a value in line with literature data.

In a meta-analysis of 611,583 subjects from 5 registries in different countries, an overall

mortality rate of 12.1% was observed, with wide variations between countries, probably related

to the different age distributions (16). In our series, 7 of the 9 exitus were over 80 years of age

(77.8%), and only 1 was under 60 years of age (11.1%); in the remaining, age data were not

available.

In relation to possible prognostic factors, our data show a higher frequency of exitus in older

individuals with arterial hypertension, chronic pulmonary disease, and atrial fibrillation. These

types of associations have been confirmed in multiple studies (1, 6, 8, 9, 17) and are explained

by the role of the angiotensin-converting enzyme receptor (ACE-2). Many elderly patients with

the aforementioned comorbidities are treated with angiotensin-converting enzyme inhibitors

(ACEi) or angiotensin II receptor blockers (ARBs), which markedly increase ACE-2 expression.

Although it has been repeated during the pandemic that the COVID-19 virus does not

discriminate among patients, it has been shown that the most disadvantaged social groups have

a higher frequency of infection and worse prognosis. Several factors explain the greater

vulnerability of disadvantaged social groups. Living in small spaces with a high number of

cohabitants and without outdoor spaces, precarious jobs without the possibility of teleworking

and the use of public transport increase the risk of respiratory infections and reduce the

possibility of social distancing. At the same time, poorer access to health services and higher

prevalence of chronic diseases worsen the prognosis. In addition to these factors, poor working

conditions, low income, and job and financial uncertainty are also known to trigger stress

mechanisms that decrease the competence of the immune system and increase susceptibility

to infections and the adoption of risky behaviors (18-20).

The PCC "Buenos Aires" belongs to Vallecas, one of the most disadvantaged neighborhoods in

Madrid. Due to the characteristics of the population attended at this center, one of our

objectives was to analyze the role of living conditions on patient prognosis. We did not obtain

results in this regard, although it is true that since this was a retrospective design, the availability

of this information in the clinical history is limited.

This study presented has some strengths and is not without limitations. The main strength is its

population base. Despite not including secondary care centers, it is very likely that the patients

seen in PC centers are sufficiently representative, since it is the first gateway to the system. It is

a population-based study and hospital care was not the first option for many patients during the

months of highest virus circulation.

The limitations also include problems of representativeness due to the peculiarities of the

population of Vallecas, which cannot be extrapolated to other areas of Madrid, and the possible

loss of more serious cases that went directly to the hospital. Another limitation of retrospective

studies is the possibility of under-registration, which has been particularly striking in the

variables on socioeconomic determinants. Finally, the small sample size and the loss of

information on some variables have not allowed multivariate analysis of mortality determinants.

Despite these limitations, we believe that the study reflects the reality of clinical practice and adequately describes the characteristics and risk factors of patients with COVID-19 infection in the PC setting. Knowledge of the burden of disease is of paramount importance at this level of care as it is the gateway to the system and has a key role in prevention, protection, promotion and treatment of individuals and communities. PC professionals are particularly concerned about the consequences of COVID on health; the decrease in acute consultations or for preventive activities as well as the delay in chronic patients' management will have a profound impact on the psychological and socioeconomic well-being of populations. This impact is already visible in vulnerable people and will continue in the medium and long term (21, 22). In these times, the holistic view of PC and the need to strengthen and rethink the system in order to increase its efficiency are of particular importance. The availability of studies at this first level is fundamental for this task. Therefore, knowledge of the characteristics and prognostic factors of SARS-CoV-2 infection in the primary care setting may be the first step in improving disease management, reducing the associated burden, and facilitating larger-scale studies of the predictable impact of SARS-CoV-2 infection in the first link of the health care system.

REFERENCES:

- 1. Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): A literature review. Journal of infection and public health. 2020;13(5):667-73. Epub 2020/04/29.
- 2. OMS. Vías de transmisión del virus de la COVID-19: repercusionees para las recomendaciones relativas a las precauciones en materia de prevención y control de las infecciones. 2020 [04-07-2020]; Available from: https://www.who.int/es/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations.
- 3. Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLoS pathogens. 2020;16(5):e1008536. Epub 2020/05/23.
- 4. Cevik M, Bamford CGG, Ho A. COVID-19 pandemic-a focused review for clinicians.

 Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020;26(7):842-7. Epub 2020/04/29.
- Consumo MdSy. Enfermedad por coronavirus (CCOVID-19). Actualización nº 290 (14-01-2021). 2020 [04-07-2020]; Available from:
 https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documento
 s/Actualización 290 COVID-19.pdf.
- 6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. Jama. 2020. Epub 2020/02/25.
- 7. Nanda A, Vura N, Gravenstein S. COVID-19 in older adults. Aging clinical and experimental research. 2020;32(7):1199-202. Epub 2020/05/12.

- 8. Shahid Z, Kalayanamitra R, McClafferty B, Kepko D, Ramgobin D, Patel R, et al. COVID-19 and Older Adults: What We Know. Journal of the American Geriatrics Society. 2020;68(5):926-9. Epub 2020/04/08.
- 9. Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology. 2020;39(6):1011-9. Epub 2020/04/16.
- 10. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary postmortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. The Lancet Infectious diseases. 2020. Epub 2020/06/12.
- 11. Trivedi N, Verma A, Kumar D. Possible treatment and strategies for COVID-19: review and assessment. European review for medical and pharmacological sciences. 2020;24(23):12593-608. Epub 2020/12/19.
- 12. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. Jama. 2020;324(13):1317-29. Epub 2020/09/03.
- 13. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA internal medicine. 2021;181(1):32-40. Epub 2020/10/21.
- 14. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. Journal of medical virology. 2020;92(6):548-51. Epub 2020/02/26.

15. Zhao J, Zhao S, Ou J, Zhang J, Lan W, Guan W, et al. COVID-19: Coronavirus Vaccine Development Updates. Frontiers in immunology. 2020;11:602256. Epub 2021/01/12.

Table 1. - Description of the sample

Characteristics	N total	n (%)
Sociodemographics		
Men	70	36 (51.4%)
Country of origin	67	
• Latin		12 (18.2%)
• Spain		53 (80.3%)
Romania		1 (1.5%)
Occupation	62	
 Unemployed or retired 		33 (53.3%)
 Social-health 		12 (19.3%)
 Cleaning 		3 (4.8%)
 Supermarkets 		2 (3.2%)
Construction		4 (6.4%)
 Industry 		3 (4.8%)
 Courier/transportation 		3 (4.8%)
Security		2 (3.2%)
Smoking	69	· · ·
No smoker		54 (78.3%)
• Ex - smoker (>1 year without smoking)		13 (18.8%)
Current smoker		2 (2.9%)
Comorbidity		, ,
Hypercholesterolemia	70	25 (35.7%)
High blood pressure	70	34 (48.6%)
Overweight	68	32 (47.1%)
Hypothyroidism	70	12 (17.4%)
Stroke/TIA	70	7 (10.0%)
Ischemic heart disease	70	6 (8.6%)
Asthma-COPD	70	15 (21.4%)
Chronic renal disease	70	2 (2.9%)
Atrial fibrillation	70	8 (11.4%)
Active malignancy	70	2 (2.9%)
 Immunosuppression 	70	2 (2.8%)
Dementia	70	4 (5.7%)
Diabetes mellitus	70	16 (22.9%)
Concomitant treatments		20 (22.070)
Inmunosupresores	61	1 (1.6%)
• ACEs	70	17 (24.3%)
Inhaled steroids	70	6 (8.6%)
NSAIDs	70	5 (7.1%
Age	60	5 (7.1170
Mean±SD	00	59.7±20.6
Median (P25-P75)		59.1 (45.8-76.0)
Minimum-maximum		18.8 – 93.0

Table 2. - Characteristics related with the SARS-CoV-2

Characteristics	N total	n (%)
Exitus	65	9 (13.8%)
Radiological findings	49	
 Normal 		17 (34.0%)
 Unilobar/bilobar pneumonia 		8 (16.0%)
 Bilateral pneumonia 		25 (50.0%)
Symptoms		
• Coughing	67	53 (79.1%)
Dyspnea	67	43 (65.1%)
Odorophagia	66	43 (65.1%)
Headache	66	16 (24.2%)
Diarrhea	67	15 (22.4%)
Anosmia	66	5 (7.6%)
	66	6 (9.1%)
Ageusia Cutoropaus	66	2 (3.0%)
• Cutaneous	68	49 (72.1%)
• Fever Setting	66	
•	00	22 (22 20/)
Primary care		22 (33.3%)
Hospital Treatments		44 (66.7%)
	53	30 (56 6%)
Azithromycin Hydrowychloroguino		30 (56.6%)
Hydroxychloroquine Coffrigue a / Coffrigue	54	40 (74.1%)
Ceftriaxone/Cefixime	50	28 (56.0%)
Amoxicillin/clavulanate Continuation	52	3 (5.8%)
Corticosteroids Tapilingaph	52	6 (11.5%)
TocilizumabRemdesivir	52 51	2 (3.8%)
RemdesivirQuinolones		4 (12 50/)
	32	4 (12.5%)
Lopinavir-Ritonavir Lovernal and a variable harming	52 52	19 (36.5%)
Low molecular weight heparin	52	30 (57.7%)
Laboratory parameters	F0	Median (P25-P75)
 Leukocytes 	50	6485 (5300-8230)
 Lymphocytes 	48 47	1.05 (0.7-1.6)
 Platelets 		200 (151-267)
• ESR	1	69 (69-69)
• CRP	48	41.2 (7.9-120.5)
 Procalcitonin 	12	0.05 (0.03-0.095)
• LDH	36 10	280 (224-389)
 CPK 	19	79 (47-160)
Ferritin	4	510 (315-748)
• D-dimer	35	740 (270-1410)
Pro-BNP	7	510 (315-748)
• GPT	41	47 (24-72)
• GOT	37	42 (31-60)
Troponin	5	0.02 (0.02-0.03)
 Glomerular filtration 	46	740 (240-1410)
 Fibrinogen 	43	1 (1-1)

Table 3.- Living conditions

Characteristics	N total	n (%)
Number of cohabitans (including the patient)	54	
One-two		38 (70.4%)
Three to seven		14 (25.9)
Twenty		2 (3.7%)
Number of bathroom in the household	36	
 One 		21 (58.3%)
 Two or more 		15 (41.7%)
Elevator	41	73.2%
Left home at least once a week (shopping)	50	40 (80%)
Left home daily	50	38 (76.0%)
Type of transportation used	48	
Private		35 (72.9%)
• Public		13 (27.1%)

Table 4. - Comparison of groups by prognosis

	No exitus (n=56)	Exitus (n=9)	p value
Sociodemo			
Women	25 (44.6%)	6 (66.7%)	0.290
Age	55.4±18.8	84.2±12.9	<0.0001
Clinical characteristics			
Smoking			1.000
No smoker	43 (78.2%)	7 (77.8%)	
• Ex - smoker	11 (20.0%)	2 (22.2%)	
Current smoker	1 (1.8%)	-	
High blood pressure	23 (41.1%)	7 (77.8%)	0.040
Overweight	23 (41.1%)	5 (71.4%)	0.226
Ictus/TIA	5 (8.9%)	2 (22.2%)	0.247
Asthma/COPD	7 (12.6%)	5 (55.6%)	0.008
Atrial fibrillation	3 (5.4%)	5 (55.6%)	0.001
Diabetes	11 (19.6%)	3 (33.3%)	0.392
Fever	43 (76.7%)	5 (55.6%)	0.225
Cough	44 (80.0%)	7 (77.8%)	1.000
Disnea	36 (65.4%)	6 (66.7%)	1.000
Headache	15 (27.3%)	1 (1.1%)	0.430
Diarrhea	13 (23.6%)	1 (11.1%)	0.670
Pneumonia	27 (64.3%)	5 (83.3%)	0.648
Azitromizin	25 (56.8%)	3 (42.9%)	0.687
Hydroxycloroquine	32 (72.7%)	5 (71.4%)	1.000
Ceftriaxone/Cefixime	23 (54.8%)	5 (83.3%)	0.379
Steroids	5 (11.6%)	1 (14.3%)	1.000
Lopinavir-Ritonavir	16 (37.2%)	2 (28.6%)	1.000
Heparin	24 (54.5%)	4 (66.7%)	0.683
Living conditions			
Number of cohabitans			0.121
One-two	17 (56.7%)	4 (80.0%)	
Three-Seven	13 (28.3%)	-	
• Twenty	1 (2.2%)	1 (20.0%)	
Number of bathrooms in the househols			0.261
• One	17 (56.7%)	3 (100%)	
Two or more	13 (43.3%)	-	
Elevator	25 (71.4%)	3 (100%)	0.552
Left home at least once a week (shopping)	35 (83.3%)	2 (40.0%)	0.057
Left home daily	32 (76.2%)	4 (80.0%)	1.000
Type of used transport			0.286
Private	31 (75.6%)	2 (50.0%)	
Public	10 (24.4%)	2 (50.0%)	